Liquidia (LQDA) has seen its stock price move recently, prompting some investors to take a fresh look at the company’s performance over the past month. Shares have climbed 30%, raising questions about what is behind the momentum.
See our latest analysis for Liquidia.
While Liquidia’s latest 30% surge in share price over the past month has drawn attention, it caps off a period of strong momentum. The stock is now up 140.58% year-to-date and boasts a 1-year total shareholder return of 173.33%. The rally suggests that investors see significant growth potential ahead, with confidence building around the company’s outlook despite recent ups and downs.
If this kind of upward momentum interests you, now’s a smart time to broaden your search and discover fast growing stocks with high insider ownership
But after such impressive gains, is Liquidia’s current share price truly undervalued? Or have markets already accounted for its future growth prospects, leaving limited room for upside?
At Liquidia’s last closing share price of $29.11, the stock is valued at 36.6 times its annual revenue, a level that stands far above typical peers and broader sector averages.
The price-to-sales (P/S) ratio measures how much investors are willing to pay for each dollar of a company’s revenue. For biotech and pharmaceutical firms, the P/S ratio is significant because many companies in these sectors operate at a loss while awaiting product approvals or scaling their revenues. This makes P/S a popular tool for benchmarking value relative to commercial traction.
Liquidia’s current P/S multiple is substantially higher than the US Pharmaceuticals industry average of 4x and also exceeds the peer group average of 2.6x. Compared to its estimated fair P/S ratio of 15.2x, the stock appears substantially overvalued on this metric. This suggests the current price builds in considerable optimism for future growth or market success beyond what has materialized so far.
Explore the SWS fair ratio for Liquidia
Result: Price-to-Sales of 36.6x (OVERVALUED)
However, uncertainties remain if Liquidia’s revenue growth slows or product setbacks occur, potentially putting pressure on today’s elevated valuation.
Find out about the key risks to this Liquidia narrative.
While the market is pricing Liquidia at a hefty revenue multiple, our DCF model offers a sharply contrasting picture. According to our analysis, Liquidia’s current share price is trading 85% below its fair value estimate. This approach suggests significant long-term upside could exist if the company meets its growth projections. Does this signal an overlooked opportunity, or is the market doubting the future?
